Latest News for: jaspis

Edit

Ryvu Therapeutics Announces Dosing of the First Patient in the JASPIS-01 Phase II Study of Dapolsertib (MEN1703/SEL24) for the Treatment of r/r DLBCL

Pharmiweb 27 Mar 2025
The primary goal of the JASPIS-01 study is to assess the safety and anti-tumor activity of dapolsertib, both as a monotherapy and in combination with glofitamab for the treatment of patients with DLBCL.
  • 1
×